Nivolumab
Nivolumab is an anti-programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1, a checkpoint control. PD-1 is a negative regulator of T-cell activation and proliferation, meaning PD-1 engagement will turn the immune response off, essentially acting as a brake to an immune reaction.
Nivolumab is indicated as treatment for various cancer types including:
- Classic Hodgkin lymphoma
- Colorectal cancer
- Esophageal adenocarcinoma
- Gastric cancer
- Gastroesophageal junction cancer
- Hepatocellular carcinoma
- Malignant pleural mesothelioma
- Advanced melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Squamous cell carcinoma of the head and neck
- Urothelial carcinoma
Provider Resources
